Baird Doubles Down on Albemarle, Sees 33% More Upside
Investment firm Baird has upgraded chemical manufacturer Albemarle to ‘outperform’ from ‘neutral’. Analyst Ben Kallo nearly doubled his price target to $210, implying a potential 33% upside from current levels.